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Sandra Cohen, Thomas Kiss, Silvy Lachance, Denis Claude Roy, Guy Sauvageau,
Lambert Busque, Imran Ahmad, Jean RoyAutologous stem cell transplantation (ASCT) prolongs survival in patients with relapsed follicular lymphoma.
ASCT is usually not curative, however. Myeloablative allogeneic transplantation has produced long-term sur-
vival at a cost of significant transplantation-related mortality (TRM), whereas reduced-intensity transplanta-
tion entails less TRM but has a higher relapse rate. We thus initiated a protocol consisting of ASCT followed
by nonmyeloablative allogeneic transplantation (NMT) for relapsed follicular lymphoma to mimic myeloabla-
tive allogeneic transplantation without the associated toxicity. The NMTwas non–T cell-depleted, and all do-
nors were HLA-identical siblings.We report results in 27 patients with a median age of 49 years (range, 34-65
years). Five patients demonstrated histological progression toward an aggressive lymphoma. The patients
had received a median of 3 lines of previous therapy. Disease status before ASCT included 8 patients in
complete remission, 14 in partial remission, and 5 refractory. Five patients developed grade II-IV acute
graft-versus-host disease, and 20 patients developed chronic graft-versus-host disease requiring systemic
therapy. With a median follow-up of 39 months after NMT, overall survival and progression-free survival
were 96% at 3 years. We conclude that the combined ASCT-NMT strategy appears to be safe, with excellent
progression-free survival even in refractory and transformed cases. This novel approach warrants further
investigation in larger prospective studies.
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subtype of non-Hodgkin lymphoma. The median age
at diagnosis is 59 years. Various treatment options
are available, but no curative standard therapy has
yet been identified. High-dose chemotherapy followed
by autologous stem cell transplantation (ASCT) pro-
longs progression-free survival (PFS) as well as overall
survival (OS) in patients with relapsed follicular lym-
phoma [1-4]. But relapse rates after this procedure
are high, and long-term toxicities, such as secondaryBlood and Marrow Transplant Program, Maisonneuve-
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Myeloablative allogeneic transplantation is consid-
ered a curative treatment for follicular lymphoma with
a low relapse rate; however, enthusiasm for this proce-
dure is hamperedbyahigh transplantation-relatedmor-
tality (TRM) of 18%-38% [10-12]. Reduced-intensity
nonmyeloablative allogeneic hematopoietic stem cell
transplantation (NMT) was designed to decrease the
high TRM associated with myeloablative transplanta-
tion, thereby extending access to this treatment to
older and more medically unfit patients [13-17].
Consequently, the use of reduced-intensity allogeneic
NMT has increased considerably in recent years, espe-
cially in patients with follicular lymphoma, who gener-
ally are older and more heavily pretreated. NMT
relies mainly on the graft-versus-lymphoma effect for
disease eradication, and OS rates are comparable to
those obtained with a myeloablative regimen [18-24].
However, relapse rates are higher with NMT [25,26].
We hypothesized that a tandem strategy composed
of ASCT followed byNMTwouldmimic amyeloabla-
tive transplantation without the associated significant951
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would be reduced to a minimum through high-intensity
cytoreductive therapy (ASCT) followed by adoptive im-
munotherapy (NMT) to eradicate minimal residual dis-
ease. We report the results of such a protocol initiated
in 2003 for patients with relapsed follicular lymphoma.MATERIALS AND METHODS
Eligibility Criteria
This prospective cohort study was conducted at
Maisonneuve-Rosemont Hospital in Montreal,
a 725-bed tertiary care hospital accredited by the
Foundation for Accreditation of Cellular Therapy.
All patients were treated and followed at a single site
by the same transplantation team, except for 1 patient
who underwent ASCT at a collaborating center.
Throughout the study period, institutional practice
guidelines recommended ASCT for patients with fol-
licular lymphoma relapsing within 24 months of the
last treatment. In addition, patients with follicular
lymphoma were invited to participate in this protocol
either before undergoing ASCT or after recovering
from ASCT if they were 18-65 years old and had an
HLA-identical sibling donor. Patients in first relapse
were eligible if they had transformed or refractory dis-
ease or progression within 18 months after their last
treatment. All patients in second relapse were eligible.
At disease progression, before ASCT, all patients
received 2-4 cycles of debulking chemotherapy with
the aim of obtaining at least a partial remission, with
ESHAP (etoposide, methylprednisolone, cytarabine,
cisplatin) [27], MINE (mesna, ifosfamide, mitoxan-
trone, etoposide) [28], or ICE (ifosfamide, carboplatin,
etoposide) [29] with or without rituximab, at the refer-
ring physician’s discretion. Patients with chemorefrac-
tory disease (ie, a response rate of\50% of the product
of length by width of nodes after debulking chemo-
therapy) were not excluded, because it was hypothe-
sized that ASCT would act as an intensive salvage
regimen to achieve a minimal disease state before
NMT. Histological progression to an aggressive lym-
phoma (grade 3 follicular or diffuse large cell lym-
phoma) was allowed. Exclusion criteria included
absence of a 6/6 sibling donor, pregnancy, cardiac ejec-
tion fraction \40%, Eastern Cooperative Oncology
Group performance status score $3, serum bilirubin
or alanine aminotransferase more than twice the upper
limit of normal, creatinine clearance \50 mL/min,
forced expiratory volume in 1 second or corrected dif-
fusion capacity of the lung for carbonmonoxide\45%
of predicted value, and HIV seropositivity. Patients
unable to participate were returned to their commu-
nity oncologists and not followed prospectively by
our transplantation team. The study protocol was ap-
proved by our hospital’s Institutional Review Board.Pretransplantation and Posttransplantation
Evaluation
Pretransplantation evaluation consisted of history
and physical examination; blood draws for complete
blood count and differential (CBC), chemistry panel,
b-2 microglobulin, and viral serologies for herpes sim-
plex virus (HSV), cytomegalovirus (CMV), hepatitis
B and C, HIV, varicella zoster virus (VZV), human
T-lymphotropic virus 1 and 2, and syphilis; computed
tomography (CT) of the chest, abdomen, and pelvis;
unilateral bone marrow aspiration and biopsy; pulmo-
nary function tests; and cardiac ejection fraction eval-
uation. Disease staging was performed using the Ann
Arbor criteria. Patients were evaluated at 3 months
after ASCT, before NMT, at 3, 6, and 12 months after
NMT, and every 6 months thereafter.
Posttransplantation evaluations consisted of his-
tory and physical exam, CBC, and a blood chemistry
panel. Chest, abdomen, and pelvis CT scans were per-
formed routinely at 3 months after ASCT, before
NMT, and 3 months after NMT. Subsequent radio-
logic imaging was left to the discretion of the treating
physician; positron emission tomography (PET) scans
were not routinely performed. Responses were scored
using previously published standard criteria [30].
ASCT
Patients received cyclophosphamide (Cy) 1.5 g/m2
i.v. for peripheral blood stem cell mobilization. Gran-
ulocyte colony-stimulating factor (G-CSF) was started
at 5 mg/kg twice a day 24 hours after Cy administration
until completion of stem cell collection. Patients con-
sidered at high risk for mobilization failure were eligi-
ble to receive an intensified mobilization regimen with
the addition of stem cell factor [31]. A daily peripheral
blood CD341 cell count was initiated 8 days after Cy
administration, and daily apheresis was performed
when CD341 cell count was $10/mL until at least
4  106 CD341 cells/kg of recipient weight were
collected. When \2  106 CD341 cells/kg were
obtained, the patient was either remobilized with Cy1
G-CSF 1 stem cell factor with or without paclitaxel,
or sent for bone marrow harvest. The conditioning reg-
imen comprised BEAM (BCNU, etoposide, cytarabine,
melphalan) or BEAC (BCNU, etoposide, cytarabine,
Cy) [32,33] was used as the conditioning regimen.
NMT, Conditioning Regimen, and Graft-versus-
Host Disease Prophylaxis
Our NMT was designed to be entirely performed
as an outpatient procedure within 3-4 months after
ASCT, that is, at earliest complete clinical recovery,
including an Eastern Cooperative Oncology Group
performance status of 0, absence of active infection,
normal oral intake, and full mobility. The pretrans-
plantation workup included the same clinical,
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fore ASCT. The outpatient NMT conditioning regi-
men and immunosuppression withdrawal schedule
were designed to have minimal acute graft-versus-
host disease (aGVHD) and to permit the graft-
versus-tumor effect associated with chronic graft-
versus host disease (cGVHD) [34]. The conditioning
regimen consisted of Cy 300 mg/m2 i.v. daily and flu-
darabine 30 mg/m2 i.v. daily for 5 days from day -8 to
day -4, given from Monday to Friday in our ambula-
tory care facility. Tacrolimus was started at 3 mg orally
twice a day on day -8, with the dose adjusted 3 times
a week until day 150 to achieve a trough serum level
of 10-15 nmol/L, then tapered completely by day
1100. Mycophenolate mofetil (MMF), used instead
of methotrexate to avoid mucositis, was initiated at
1000 mg twice a day on day12 and discontinued with-
out tapering on day 150. MMF was not adjusted for
recipient weight, and serum level was not monitored.
Donors received G-CSF 5 mg/kg twice a day for 9
doses, and cells were collected by consecutive daily
apheresis until at least$4 106 CD341 cells/kg of re-
cipient weight had been obtained. Allogeneic stem
cells were reinfused on day 0 after storage at 4C over-
night; no attempt was made to limit the number of
CD341 cells infused [35]. Both a GVHD and cGVHD
were graded according to previously reported criteria
after exclusion of infectious and other causes; all efforts
were made to obtain a tissue biopsy specimen to con-
firm diagnosis [36,37]. Prospective assessment of
quality of life was not performed using standardized
questionnaires; instead, use of immunosuppressants
and Karnofsky Performance Status (KPS) score
served as surrogate markers.
Infectious Prophylaxis
After ASCT, trimethoprim/sulfametoxazole (one
double-strength tablet twice a day on Saturday and
Sunday) was given for Pneumocystis jirovecii prophylaxis
until day1100. Patients seropositive forHSV received
acyclovir 200 mg orally 3 times a day or 250 mg/m2 i.v.
twice a day until resolution of neutropenia and muco-
sitis. Fluconazole 200mg/day orally or i.v. was given at
the onset of moderate mucositis until its resolution or
until initiation of another systemic antifungal agent.
After NMT, trimethoprim/sulfametoxazole (one
double-strength tablet twice a day on Saturday and
Sunday) was given for P jirovecii prophylaxis starting
on day -3 and continuing until discontinuation of all
immunosuppressive therapy (or for a minimum of 6
months). Patients who were seropositive for HSV re-
ceived acyclovir 200 mg 3 times a day from day -8 to
day 121. No VZV prophylaxis was administered.
CMV-seropositive recipients or recipients of a trans-
plant from a CMV-seropositive donor were followed
using a preemptive approach of weekly quantitative
polymerase chain reaction (PCR) analysis from day114 to day 198, after which routine surveillance was
discontinued. Patients with a positive CMV PCR
result were promptly treated with i.v. ganciclovir or
oral valganciclovir for a minimum of 4 weeks accord-
ing to a standard dosage algorithm. No other antimi-
crobial or antifungal prophylaxis was administered.
Immunoglobulins and G-CSF were not routinely
administered after NMT.
Engraftment
Chimerism studies were performed using short
variable tandem repeats by PCR assay (GenePrint
STR System; Promega, Madison, WI) in both lym-
phocytes and neutrophils every 2 weeks for the first
8 weeks, then monthly for 2 months, and then every
3 months thereafter. Complete donor chimerism
(CDC) was considered achieved when $95% of lym-
phocytes were of donor origin.
Statistical Analysis
The primary endpoint of this study was the safety
of the tandem transplantation protocol as assessed by
the TRM. Additional objectives included response
rates, PFS, OS, infectious complications, and incidents
of aGVHD, cGVHD, and graft failure. Kaplan-Meier
incidence estimates for aGVHD and cGVHD, PFS,
and OS were calculated using the Prism 5.0 statistical
package (GraphPad Software, San Diego, CA). PFS
and OS were calculated from the day of NMT until
progression or death, respectively. Follow-up was
completed as of February 17, 2010.RESULTS
Demographic Data
Between April 2003 and April 2008, a total of 27
patients were enrolled and followed prospectively on
the tandem protocol. Median follow-up after NMT
was 39 months (range, 7-75 months). Patient charac-
teristics are presented in Table 1. The study group
had a median age of 49 years (range 34-65) and was
predominately male (70%). Twenty-five patients had
follicular lymphoma, and the other 2 had an imprecise
diagnosis (follicular versus marginal zone lymphoma)
despite histopathologic review. Five patients had
evidence of histological progression toward an aggres-
sive lymphoma (1 follicular grade 3A, 3 follicular grade
3B, and 1 diffuse large cell lymphoma). The median
time from diagnosis to ASCT was 34 months (range,
14-131 months), and the median number of previous
lines of therapy was 3 (range, 2-6). Eight patients had
received only 2 previous therapies; 2 of these patients
had transformed disease, whereas the others had re-
lapsed within 18 months (range, 4-15 months) of
front-line therapy. Seven patients (26%) had never
been exposed to rituximab. Twenty-two patients
Table 1. Characteristics of 27 PatientsWhoUnderwentASCT
Followed by NMT
Age, yr, median (range) 49 (34-65)
Male sex, n (%) 19 (70)
Type of lymphoma
Follicular grade 1-2 20 (74)
Follicular grade 1-2 versus marginal zone 2 (7)
Transformed* 5 (19)
Number of chemotherapy regimens before
transplantation
2 8 (30)
3 9 (33)
4 8 (30)
$5 2 (7)
Disease status before ASCT
CR 8 (30)
PR 14 (52)
Refractory 5 (19)
Disease status before NMT
CR 13 (48)
CRu 2 (7)
PR 8 (30)
Stable disease 2 (7)
Not assessed 2 (7)
Donor/recipient CMV status
2/2 15 (56)
2/+ 3 (11)
+/2 6 (22)
+/+ 3 (11)
Donor/recipient sex pair: female/male 8 (30)
CRu indicates complete remission unconfirmed; PR, partial remission.
*Transformed lymphomas included follicular grade 3A (n5 1), follicular
grade 3B (n 5 3), and diffuse large B cell (n 5 1).
954 Biol Blood Marrow Transplant 18:951-957, 2012S. Cohen et al.(81%) had chemosensitive disease at time of ASCT,
and 5 (19%) had chemorefractory disease, including
1 case of transformed lymphoma.ASCT
Fourteen patients (52%) were conditioned with
BEAC and 13 (48%) with BEAM. Twenty-two pa-
tients received a median of 5.3  106 CD341 cells/
kg (range, 2.3-11.3 106); data is unavailable for 1 pa-
tient who underwent ASCT in 2003 at a collaborating
center that monitored only colony-forming units.
Four patients failed to mobilize an adequate number
of stem cells, including 2 patients who had received
an intensified mobilization regimen of Cy, G-CSF,
and stem cell factor with or without paclitaxel. Bone
marrow was harvested from these 4 patients, and a me-
dian of 2.61  108 nucleated cells/kg (range, 1.65-8.3
 108) were collected and infused at the time of trans-
plantation. Seventeen patients received daily G-CSF
administration starting on day17 until neutrophil en-
graftment, which became our institution’s standard
practice in 2004. G-CSF was administered in 3 other
patients, 2 with serious infectious complications and
1 with delayed engraftment. The median time to neu-
trophil engraftment was 11 days (range, 9-21 days),
and the median time to platelet engraftment was 15
days (range, 11-42 days). No ASCT-related deaths oc-
curred. Responses to ASCT included 13 complete re-
missions (CR; 48%), 2 CR unconfirmed (7%), 8 partial
remissions (30%), and 2 stable disease (7%). Two pa-
tients did not undergo adequate imaging studies before
NMT and could not be assessed. One patient withpersistent cytopenias after ASCT had a bone marrow
aspirate suggestive of secondary myelodysplasia.
NMT
Twenty-six patients received the planned condi-
tioning regimen of fludarabine/cyclophosphamide;
the patient with secondary myelodysplasia received
busulfan 3.2 mg/kg i.v. for 2 days with fludarabine 45
mg/m2 i.v. for 4 days. The median interval between
ASCT and NMT was 133 days (range, 75-238 days).
Only 12 patients (44%) were at risk for CMV disease.
Eight males received a graft from a female donor.
Grafts and Engraftment
The median number of infused allogeneic CD341
cells was 8.2  106/kg (range, 3.2-29.2  106/kg). Me-
dian time to neutrophil engraftment was 13 days
(range, 0-19 days), with a median of 11 days (range,
0-23 days) of severe neutropenia (\0.5  109/L).
This number is likely an overestimate in view of only
thrice-weekly CBCs. Two patients (7%) received
G-CSF for neutropenic fever. Only 2 patients had a
platelet count #20  109/L and required transfusions
(2 and 4 transfusions, respectively). RBC transfusions
(2-4 units) were required in 6 patients. Twenty-two
of 26 patients (85%) achieved CDC by day 1120,
and 26 of 27 patients (96%) did so by day 1180. No
patient required donor leukocyte infusion to achieve
CDC, and no graft failure occurred.
GVHD
Fourteen patients discontinued tacrolimus by
day1100. One patient had to stop tacrolimus early af-
ter transplantation because of secondary encephalopa-
thy; MMF was continued beyond day 1100 in this
patient. The treating physicians decided to prolong
immunosuppressive therapy in 8 patients because of
the possibility of some mild cGVHD or concern for
cGVHD in a patient in CR and thus at low risk for re-
lapse; 3 of these patients continued tacrolimus until
day 1130, and the other 5 did so until day 1180.
At a median of 128 days after transplantation
(range, 43-138 days), only 5 patients developed grade
II-IV aGVHD (incidence, 19%; 95% confidence
interval [CI], 2%-50%), including 1 case of grade II
and 4 cases of grade III. Three patients had delayed-
onset aGVHD, and 2 had classic aGVHD. The skin
was involved in 2 patients, the gut in 3 patients, and
the liver in 1 patient. Twenty patients developed
cGVHD requiring systemic immunosuppressive ther-
apy (incidence, 74% at 3 years; 95% CI, 62%-83%).
According to the National Institutes of Health
cGVHD consensus criteria [36], 10 patients (50%)
had moderate disease and 10 (50%) had severe disease.
A median of 2 immunosuppressive agents (range, 1-6)
was required for cGVHD treatment. At the time of last
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Figure 1. Kaplan-Meier probability of taking any immunosuppressive
medication (IS) in 27 patients with follicular lymphoma treated with
a tandem ASCT-NMT strategy. The solid line represents the entire
cohort; the dashed line represents patients who developed cGVHD.
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Figure 2. Kaplan-Meier probability of OS and PFS in 27 patients with
follicular lymphoma treated with a tandem ASCT-NMT strategy.
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months after NMT, 14 of 20 patients (70%) were off
immunosuppressive therapy. For the whole cohort,
the probability of taking any immunosuppressive med-
ication after NMT decreased steadily over time and
was estimated as 39% at 2 years and 27% at 3 years.
In patients with cGVHD, the probability of taking
systemic immunosuppression was estimated as 53%
at 2 years and 36% at 3 years (Figure 1). Patients
with cGVHD discontinued immunosuppression at
a median of 26 months after NMT. The median
KPS score at last follow-up for all living patients was
90% (range, 70%-100%).
Transplantation-Related Complications and
Outcomes
Two patients, both CMV-seropositive, developed
CMV viremia, for an incidence of 17% in patients at
risk. No patient developed CMV disease. VZV reacti-
vation was common, with an incidence of 56% (17
episodes in 15 patients) after a median follow-up of
42 months after ASCT. No patient had an invasive
fungal infection. Although our NMT regimen was de-
signed as an outpatient procedure, 7 patients (26%)
were admitted to the hospital within the first 100
days, 6 for infectious complications and 1 for severe
autoimmune hemolytic anemia.
Most patients (n 5 24; 89%) achieved CR after
NMT. Three patients could not be classified as CR
because of persistent lymph nodes; 2 of these had
lymph nodes measuring 16 and 18 mm, and PET scans
were not performed. The third patient had a 20-mm
lymph node identified as metabolically active on
PET scan since transplantation; intriguingly, this
lymph node has remained unchanged for 6 years
despite a lack of treatment. No patient developed
progressive disease. There were no cases of therapy-
related myelodysplasia/acute myelogenous leukemia
after NMT, and the patient who developed myelodys-
plasia after ASCT remains in remission. Only 1 patient
died from GVHD-related complications, at 7 months
after NMT; thus, TRM is evaluated at 4% (95% CI,0-63%). With a median follow-up of 39 months
(range, 7-75 months) after NMT, estimated OS and
PFS at 3 years is 96% (Figure 2); 16 patients are alive
without progression beyond 3 years after NMT.
DISCUSSION
ASCT is widely considered the standard of care for
the treatment of relapsed follicular lymphoma in
patients without significant comorbidities. Unfortu-
nately, however, most patients will relapse after
ASCT. Although myeloablative ASCT has been asso-
ciated with a high TRM (30%-38%), it has led to en-
couraging long-term survival rates (event-free survival
of 43% at 4 years and 45% at 5 years) [11,12]. There
have been several reports of NMT with lower TRM
(7%-15%) but higher relapse rates compared with
myeloablative transplantation [13,14,25,26].
To our knowledge, this is the first report of a trial
incorporating a novel approach to treating follicular
lymphoma comprising ASCT for maximal cytoreduc-
tion followed by allogeneic NMT for immunotherapy
by means of the graft-versus-lymphoma effect. Our re-
sults indicate that this tandem transplant strategy is safe
and well tolerated, with a lowTRMof 4%. In addition,
this approach yielded an excellent PFS and OS of 96%
at 3 years, with amedian follow-upof 39months.These
encouraging results are observed despite the inclusion
of patients with transformed and refractory disease,
which are traditionally associated with inferior survival
rates after NMT [18,22,38]. We speculate that ASCT
is conducive to achieving and maintaining a state of
minimal disease of sufficient duration to allow
eradication of any residual disease by a graft-versus-
lymphoma effect. In that respect, our approach could
be particularly adapted for patients with bulky, aggres-
sive, or less-sensitive disease at the time of ASCT com-
paredwith patientswithminimal disease and nohistory
of transformation for whom upfront NMT could be
sufficient for long-term disease control [23]. This will
need to be clarified in future studies.
Our results compare favorably to those from previ-
ous studies of myeloablative and nonmyeloablative
transplantation [11,12,18-24]. Khouri et al. [23] have
956 Biol Blood Marrow Transplant 18:951-957, 2012S. Cohen et al.published the most impressive results thus far, with
a disease-free survival of 83% at 5 years after NMT
with the addition of rituximab to the conditioning reg-
imen. Of note, a significant proportion of patients in
their cohort (49%) had received only 2 previous lines
of therapy, all of their patients had chemosensitive dis-
ease at time of transplantation, and patients with trans-
formation into diffuse large cell lymphoma were
excluded [23]. Thus, our patients had more advanced
and aggressive disease and were consequently at
greater risk for relapse. Remarkably, we observed no
disease progression. Although all previous studies
have reported lower event-free survival rates of 38%-
69% at 2-5 years after transplantation, our median
follow-up (39 months) is shorter than that in the larger
cohorts reported by Thomson et al. (43 months) and
Khouri et al. (60 months) [11,12,18-24]. In addition,
we did not perform routine PET scans during long-
term follow-up, and thus potentially might have
missed early, asymptomatic relapses. Finally, consider-
ing that patients could enroll after ASCT, it is also
possible that potential referrals might have been
excluded because of patients’ poor medical condition
or progressive disease after ASCT, resulting in
a selection bias. We believe this to be unlikely, given
the low probability of significant morbidity after autol-
ogous transplantation and the fact that refractory
disease was not an exclusion criterion in our program.
The incidence of aGVHD in the present study is
strikingly low, likely due to our immunosuppressive
regimen, as previously reported [34]. We believe that
this low incidence of aGVHD helps explain the low
TRM in our cohort. In contrast, the incidence of
cGVHDof 74% is high but without associatedmortal-
ity. We speculate that this high rate of cGVHD may
protect patients from relapse, thus explaining the
absence of progressive disease after transplantation in
this high-risk cohort. Despite the high incidence of
cGVHD, the probability of taking systemic immuno-
suppressive therapy (27% at 3 years) is comparable to
that reported in previous studies [39] and KPS score
(90%) was excellent at last follow-up. Of note, the in-
cidence of CMV viremia was particularly low in our
cohort, possibly related to the low number of seropos-
itive recipients (n 5 6) or the low incidence of
aGVHD, a known risk factor for CMV infection
[40,41]. In contrast, VZV reactivation occurred
frequently, in 56% of our patients, which is not
surprising given that both cGVHD and lymphoid
malignancy have been described as risk factors
[42,43]. Following this observation, all VZV-
seropositive patients now receive prophylaxis with
valacyclovir 500 mg twice a day for a minimum of 1
year after allogeneic transplantation [44].
In conclusion, our results are from a prospective,
single-institution, phase II study. It will be important
to reproduce these results in a multi-institutional set-ting with more patients. Longer follow-up and pro-
spective, standardized assessment of quality of life in
survivors are needed to ascertain that the excellent
KPS will be maintained over time with acceptable
morbidity. In addition, the possibility of selection
bias in our study must be considered, even though
we did not exclude patients with high-risk disease,
such as transformed and refractory cases. Neverthe-
less, we believe that this study is a step forward in
developing more effective approaches to treating fol-
licular lymphoma. Finally, a tandem approach should
be considered in patients with bulky, transformed, or
refractory follicular lymphoma for whom allogeneic
transplantation is contemplated.
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